Previous studies have reported that pharmacological targeting of GSK-3 and Nrf2 exerts neuroprotective effects (20), and that AKT, GSK-3β, and Nrf2 activity is responsible for improvements in PD symptoms. Here, GSK3B is linked to Parkinson disease.